Search Results 621-630 of 17866 for Coagulation

1. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   Adequate coagulation function defined as prothrombin time or international normalized ratio ≤ 1.5 × ULN unless the participant is receiving anticoagulant ...

2. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies - Mayo Clinic

   History of bleeding disorder or predisposing conditions, blood clotting, or clinically significant abnormal results on coagulation profile at Screening, as ...

3. A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

   subjects with liver metastases); Coagulation: INR, PTT ≤1.5 × ULN. Specimens must be collected within 10 days prior to the start of study combination ...

4. A Study to Assess the Feasibility of Combining Clinically- indicated MitraClip Transcatheter Mitral Valve Repair (TMVR) and Watchman Left Atrial Appendage Occlusion (LAAO)

   Family history of VTE or of inherited prothrombotic disorder, recurrence/extension of thrombosis while adequately anti-coagulated. The patient is actively ...

5. Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery - Mayo Clinic

   Any congenital coagulation disorder. Asplenia (anatomic or functional). History of photosensitivity or active skin disease that, in the opinion of the ...

6. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA) - Mayo Clinic

   - History of coagulation disorder. - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results ...

7. AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE - Mayo Clinic

   Subjects with abnormal coagulation or who require ongoing complete anticoagulation. Bleeding diathesis. Altered anatomy of the upper gastrointestinal tract ...

8. Device Evaluation for Point of Care Anticoagulation Testing - Mayo Clinic

   About this study. The purpose of this study is: To Evaluate and validate the Roche Coaguchek XS Plus analyzer at MCA to replace the ITC Hemochron Jr.

9. Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. - Mayo Clinic

   Acceptable coagulation parameters including international normalized ratio (INR) <1.5 and partial thromboplastin time (PTT) ≤ institutional ULN in the ...

10. Study of SBP-101 in Pancreatic Cancer - Clinical Trials

    Adequate bone marrow, hepatic, renal and coagulation function as defined by the following: Absolute neutrophil count ≥1.5 x 10^9/L, Hemoglobin ≥9.0 g/dL ...